GlassScriptPhysician profile
Binu Malhotra
NPI 1104023118
$5,042.79
in general payments reported to CMS, 2019-2025
62 companies · $2,935 in 2025
The $2,935 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $101 · 2020: $23.49 · 2021: $34.49 · 2023: $22.04 · 2024: $1,927 · 2025: $2,935.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,658 · Education: $226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,657.61 |
| Education | $225.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $330.50 | 2024-2025 | |
| Janssen Biotech, INC. | $296.57 | 2024-2025 | Darzalex, Tecvayli, Talvey |
| Genentech USA, INC. | $252.19 | 2019-2025 | Venclexta, Polivy, Tecentriq |
| Astrazeneca Pharmaceuticals LP | $247.24 | 2024-2025 | Calquence, Imfinzi, Lynparza |
| Eisai INC. | $243.38 | 2024-2025 | |
| Astellas Pharma US INC | $227.89 | 2024-2025 | Xospata, Xtandi |
| Pfizer INC. | $217.64 | 2024-2025 | |
| Tempus Ai, INC | $196.12 | 2024-2025 | Xt Cdx |
| Incyte Corporation | $195.10 | 2024-2025 | Jakafi |
| Merck Sharp & Dohme LLC | $189.79 | 2024-2025 | Keytruda, Welireg |
| Abbvie INC. | $140.20 | 2024-2025 | |
| Glaxosmithkline, LLC. | $134.02 | 2024-2025 | Ojjaara, Zejula, Jemperli |
| E.R. Squibb & Sons, L.L.C. | $119.23 | 2021-2025 | Opdivo, Opdualag |
| Genzyme Corporation | $109.68 | 2024-2025 | |
| Daiichi Sankyo INC. | $109.15 | 2024-2025 | Enhertu, Datroway |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $106.30 | 2024-2025 | Orserdu |
| Array Biopharma INC | $104.59 | 2024-2025 | Braftovi, Mektovi, Tukysa |
| Seagen INC. | $98.65 | 2024 | |
| Genmab U.S., INC. | $94.93 | 2024-2025 | Epkinly |
| Amgen INC. | $92.33 | 2025 | Imdelltra (Amg757) |
| Legend Biotech USA INC. | $92.06 | 2024-2025 | Carvykti |
| Beone Medicines USA, INC. | $91.28 | 2025 | Tevimbra, Brukinsa |
| Celgene Corporation | $90.02 | 2019-2025 | Reblozyl, Breyanzi |
| Janssen Scientific Affairs, LLC | $78.95 | 2019-2025 | Akeega, Balversa, Erleada |
| Alexion Pharmaceuticals, INC. | $75.53 | 2024-2025 | Ultomiris |
| Gilead Sciences, INC. | $73.10 | 2021-2025 | Trodelvy |
| Ipsen Biopharmaceuticals, INC | $62.82 | 2024-2025 | Onivyde, Tazverik |
| Taiho Oncology, INC. | $53.92 | 2024 | |
| Azurity Pharmaceuticals, INC. | $53.22 | 2024-2025 | Danziten, Vivimusta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.48 | 2024-2025 | Gilotrif |
| Sun Pharmaceutical Industries INC. | $44.70 | 2024-2025 | |
| Pharmaessentia USA Corporation | $43.81 | 2024 | Besremi |
| Bayer Healthcare Pharmaceuticals INC. | $43.62 | 2025 | |
| Pharmacosmos Therapeutics INC. | $41.34 | 2024-2025 | Monoferric |
| Tersera Therapeutics LLC | $39.91 | 2019-2025 | Zoladex |
| Regeneron Healthcare Solutions, INC. | $38.16 | 2025 | Libtayo |
| Kyowa Kirin, INC. | $36.13 | 2025 | |
| Rigel Pharmaceuticals, INC. | $33.60 | 2024-2025 | Rezlidhia, Tavalisse, Gavreto |
| Exelixis INC. | $31.04 | 2024-2025 | Cabometyx |
| Sobi, INC | $30.53 | 2025 | |
| Acrotech Biopharma INC. | $30.16 | 2025 | Beleodaq |
| Aveo Pharmaceuticals, INC. | $29.11 | 2024-2025 | |
| Agios Pharmaceuticals, INC. | $26.20 | 2025 | Pyrukynd |
| Shorla Oncology INC. | $25.31 | 2025 | |
| Blueprint Medicines Corporation | $24.37 | 2025 | Ayvakit |
| Recordati_rare_diseases_inc. | $23.59 | 2025 | Enjaymo |
| Octapharma USA, INC. | $23.41 | 2025 | Octagam Immune Globulin (Human) |
| Geron Corporation | $23.25 | 2025 | Rytelo |
| Springworks Therapeutics, INC. | $22.32 | 2025 | Ogsiveo |
| Jazz Pharmaceuticals INC. | $21.48 | 2024 | |
| Apellis Pharmaceuticals, INC. | $17.84 | 2024 | Empaveli |
| Deciphera Pharmaceuticals INC. | $17.62 | 2024 | Qinlock |
| Verity Pharmaceuticals INC. | $17.13 | 2025 | Trelstar |
| Takeda Pharmaceuticals U.S.A., INC. | $16.40 | 2025 | Ninlaro |
| Servier Pharmaceuticals LLC | $15.97 | 2025 | |
| Beigene USA, INC. | $15.70 | 2025 | Tevimbra |
| Kite Pharma, INC. | $15.63 | 2024 | Yescarta |
| Syndax Pharmaceuticals, INC. | $15.31 | 2025 | |
| Puma Biotechnology, INC. | $15.29 | 2025 | |
| Myriad Genetic Laboratories, INC. | $13.87 | 2024 | Myrisk |
| Emd Serono, INC. | $13.61 | 2025 | |
| Epizyme, INC. | $11.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Binu Malhotra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.